Effects of Neuromuscular Electrical Stimulation in Muscle Architecture and Functionality of Patients After Acute Stroke

Stroke, Acute Clinical Trial

Official title:

Effects of Neuromuscular Electrical Stimulation in Muscle Architecture and Functionality of Patients After Acute Stroke

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03840954
• Other study ID #: 20180460
• Status: Not yet recruiting
• Phase: N/A
• Start date: August 30, 2019
• Est. completion date: August 30, 2022

Study information

• Verified date: June 2019
• Source: Hospital de Clinicas de Porto Alegre
• Contact: Graciele Sbruzzi, doctor
• Phone: +55(51)33577334
• Email: gsbruzzi[@]hcpa.edu.br
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Introduction: Stroke is a sudden illness, responsible for important neurological and cognitive sequelae that can result in functional limitations and dependence. It is the leading cause of neurological impairment in young adults and resting-related muscle loss is one of the major factors involved. Early rehabilitation is essential for these patients and neuromuscular electrical stimulation (NMES) has been identified as an intervention alternative due to its known effects on the prevention of muscle loss in patients with various pathologies. Objective: To evaluate the effects of NMES associated with conventional physiotherapy compared to conventional physiotherapy on muscle thickness and functionality of patients with acute stroke. Methodology: This is a randomized clinical trial, which will be performed at the Emergency and Unit Unit of the Stroke of the Hospital de Clínicas of Porto Alegre (HCPA). Patients with acute stroke, with up to 72 hours of hospital admission, who present with lower limb force deficit due to the current stroke will be included. Patients will be randomized into two groups: intervention group, who will receive the application of NMES associated with conventional physiotherapy and control group, who will receive the conventional physiotherapy of the HCPA. NMES training will be applied once a day (30 minutes of application per session with an increase of five minutes each week and gradual reduction in OFF time), five days a week until hospital discharge or up to a maximum of three weeks. The following outcomes will be assessed before and after the intervention: quadriceps and tibial thickness and quality of the quadriceps and tibialis anterior, muscle strength, stroke severity, gait, functionality and disability.

Description:

Stroke is the leading cause of neurological impairment in young adults, and early rehabilitation is essential for the recovery of these patients.

It is already known that muscle loss is one of the main factors responsible for functional disability and dependence in stroke survivors, being observed already in the acute phase and mainly in the lower limbs. The physiological mechanisms involved in stroke-related muscle loss, such as muscle inactivity, denervation, malnutrition, inflammation and metabolic disorders, among others have been reported in studies, but there is no consistent evidence regarding effective therapies to avoid muscle loss.

The NMES is already widely used for the prevention of muscular loss in patients with various pathologies. Studies have also reported the efficacy of NMES in patients with subacute or chronic stroke. In patients with acute stroke, the literature is rather scarce. The investigators are aware of only one study that evaluated the effects of NMES on muscle mass loss, but the authors did not evaluate the effects of this intervention on the physical performance or functionality of the patients. Thus, the investigators consider the importance of further studies to know the effects of NMES on muscle loss in patients with acute stroke and the need to evaluate the effects of NMES on the physical performance functionality of these patients aiming at the possibility of offering an intervention option precocious and effective for this population.

The objective of this study is to evaluate the effects of NMES associated with conventional physiotherapy compared to conventional physiotherapy in the muscular architecture and functionality of patients with acute stroke.

This is a randomized clinical trial in which the participants will be randomly divided into experimental group (EG) and control group (CG), being evaluated before and after the intervention.

The sample will be composed of hospitalized patients diagnosed with acute stroke at the Hospital de Clínicas de Porto Alegre (HCPA).

The estimated sample is 70 patients (35 in each group). Waiting for a 0.5 cm difference in muscle thickness between groups and a standard deviation of 0.68 and 2 of 0.80, with a significance level of 5%, 80% power.

Randomization will be performed through data generated by a computer program that presents the coded distribution. The sequence generation of the numbers to be randomized will be performed by a researcher blind to the study - after selection of the patients according to the eligibility criteria - keeping it confidential until the beginning of the intervention.

Data collect:

Socio-demographic data will be collected such as: age and sex; anthropometric variables:

weight, height and BMI; and clinical data: stroke region, side of hemiparesis, comorbidities, complications during the hospitalization period (eg pneumonia, need for decompressive craniectomy), functional condition prior to the current stroke, time to start physical therapy, time to onset of NMES, total time of NMES, time to reach orthostasis and time to start ambulation. These data will be obtained through the review of medical records and interviews with patients or relatives.

Assessments: The evaluations described below will be performed within 72 hours of hospital admission and repeated at hospital discharge or within 21 days.

Assessment of muscle architecture - The assessment of muscle thickness will be performed in the femoral and tibial quadriceps muscles (TA). The images will be obtained by ultrasound using the Portable Ultrasound System (Vivid i®, GE) with a linear arrangement probe (60mm, 7.5 MHz - Vivid i®, GE). The same researcher (who will be blinded for the interventions) will do all the evaluations, which will be performed with the musculature at rest.

Muscle Strength Assessment: Manual Dynamometry, Medical Research Council (MRC)

Functional and Inability Assessment: Barthel's Index Modified

Walking assessment and functional capacity: Functional Ambulation Category (FAC)

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 70
• Est. completion date: August 30, 2022
• Est. primary completion date: May 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of ischemic or hemorrhagic stroke performed by a neurologist based on clinical and neuroimaging characteristics;

• To present motor sequelae in the lower limb due to stroke.

Exclusion Criteria:

• Previous motor deficits

• Complete recovery of motor deficits before the initial evaluation;

• Conditions that prevent neuromuscular electrical stimulation such as skin lesions at the site of electrode placement, pacemaker and therapy intolerance.

• Time greater than 72 hours since hospitalization.

Related Conditions & MeSH terms

• Neuromuscular Electrical Stimulation
• Stroke
• Stroke, Acute

Intervention

Other:
• Neuromuscular Electrical Stimulation
The application of NMES will be performed with the patient positioned in the supine position in the bed. Self-adhesive electrodes will be positioned at the motor points of the quadriceps and anterior tibial muscles respectively. A symmetrical biphasic pulsed current with a frequency of 80 Hz, a pulse width of 500 µs and an intensity at the motor threshold will be applied up to the maximum tolerated by the patient. ON and OFF time and total session time will be used according to protocol with progressive increase of the total intervention time and reduction of OFF time of the NMES. The device used will be the Neurodyn II model, manufactured by IBRAMED. Patients will receive NMES for as long as they remain hospitalized or for up to 3 weeks.

Locations

Country	Name	City	State
Brazil	HCPA	Porto Alegre	Rio Grande Do Sul

Sponsors (1)

Lead Sponsor	Collaborator
Hospital de Clinicas de Porto Alegre

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quadriceps muscle thickness	Evaluated by muscular echography (cm)	three weeks
Primary	Thickness of the anterior tibial muscle	Evaluated by muscular echography (cm)	three weeks
Secondary	Functionality - Barthel Index for Activities of Daily Living	The score ranges from 0 to 100 points (90 to 100 - independent, 60 to 89 - slightly dependent, 40 to 59 - moderately dependent, 20 to 39 - severely dependent and less than 20 - totally dependent).	three weeks
Secondary	Muscle strength - Medical Research Council (MRC) Scale	The MRC score is obtained by evaluating 12 muscle groups in the upper extremities (wrist extensors, elbow flexors and abductors of the shoulder) and lower extremities (dorsal ankle flexors, knee extensors, and hip flexors). For each muscle group will be assigned a score between 0 (complete paralysis) and 5 (normal force), and the total score can vary between 0 up to 60 points.	three weeks
Secondary	Functional walking - Functional Ambulation Categories	Evaluates the degree of assistance required for ambulation. It distinguishes six categories for ambulation ability (1 to 3 - need for physical assistance during walking, 4 - requires only supervision and 5 and 6 - independent walking).	three weeks
Secondary	Dynamometry - Knee extension	Dynamometry (kg)	three weeks
Secondary	Dynamometry - ankle dorsiflexion	Dynamometry (kg)	three weeks
Secondary	Sit and stand up to 30 seconds	Assess the maximum number of times it is possible to get up and sit down in 30 seconds	three weeks
Secondary	Modified Rankin Scale	Evaluates the degree of disability and dependence in daily life with a score of 0: without any symptom at 6: death	three weeks
Secondary	10-meter walking test	Evaluates gait speed and cadence	three weeks